Filing Flows

Filing Flows › Health Care › Aligos Therapeutics (ALGS)

Aligos Therapeutics (ALGS) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Aligos Therapeutics (ALGS) Q3 2026 earnings results →

Q3 2026 Revenue up 282% year over year to $2.8M · 772¢ of every $1 of revenue lost · operating margin -773.5%

Aligos Therapeutics made $2.8M in Q3 2026 (+282% Y/Y). Operating margin -773.5%, net loss $21.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.

Revenue$2.8M
Year over year+282%
Operating margin-773.5%
Net earnings−$21.9M
Operating cash flow$1.5M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $2.8M in Q3 2026, up 282% year over year.

Operating costs exceeded revenue by $21.9M, an operating margin of -773.5%. Total costs fell 15% while revenue rose 282%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $21.9M.

Operating cash flow was $1.5M. Non-cash charges added back $300K of depreciation and $1.3M of share-based compensation. Working capital and other items added $21.7M.

Quarterly history

Aligos Therapeutics revenue by quarterAligos Therapeutics revenue by quarter$606KQ4 2024$311KQ1 2025$965KQ2 2025$741KQ3 2025$169KQ4 2025$2.8MQ1 2026$2.8MQ3 2026
Aligos Therapeutics net earnings by quarterAligos Therapeutics net earnings by quarter−$82.2MQ4 2024$43.1MQ1 2025−$15.9MQ2 2025−$31.5MQ3 2025−$19.9MQ4 2025−$23.0MQ1 2026−$21.9MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 6, 2026$2.8M+282%-773.5%−$21.9M$1.5M
Q1 202610-QMay 7, 2026$2.8M+810%-951.6%−$23.0M−$23.1M
Q4 202510-KMar 5, 2026$169K-72%n/m−$19.9M−$21.7M
Q3 202510-QNov 6, 2025$741K-41%n/m−$31.5M−$24.3M
Q2 202510-QAug 6, 2025$965K-9%n/m−$15.9M−$15.5M
Q1 202510-QMay 6, 2025$311K-55%n/m$43.1M−$20.9M
Q4 202410-KMar 10, 2025$606K-10%n/m−$82.2M−$18.4M

Charts

Aligos Therapeutics: revenue growth, year over year and quarter over quarterAligos Therapeutics: revenue growth, year over year and quarter over quarterY/YQ/Q-10%Q4 2024-55%-49%Q1 2025-9%+210%Q2 2025-41%-23%Q3 2025-72%-77%Q4 2025+400%+400%Q1 2026+282%+0%Q3 2026
Latest (Q3 2026): Y/Y +282%, Q/Q +0%.
Aligos Therapeutics: where the cash came from (+) and went (−), TTM to Q3 2026Aligos Therapeutics: where the cash came from (+) and went (−), TTM to Q3 2026Operating cash flow−$68.4MOther investing$57.8MCash drawn (+) / kept (−)$10.3MShares issued$360KNet borrowing (+) / repaid (−)−$89KOther financing$2K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Aligos Therapeutics: profit against cash, quarter by quarterAligos Therapeutics: profit against cash, quarter by quarterNet incomeOperating cash flow−$82.2M−$18.4MQ4 2024$43.1M−$20.9MQ1 2025−$15.9M−$15.5MQ2 2025−$31.5M−$24.3MQ3 2025−$19.9M−$21.7MQ4 2025−$23.0M−$23.1MQ1 2026−$1.5M−$24.9MQ2 2026−$21.9M$1.5MQ3 2026
Latest (Q3 2026): Net income −$21.9M, Operating cash flow $1.5M.
Aligos Therapeutics: diluted shares by fiscal year (split-adjusted)Aligos Therapeutics: diluted shares by fiscal year (split-adjusted)40MFY202040MFY202143MFY20223MFY20236MFY202410MFY2025
-75.3% since FY2020: buybacks shrank the count; earlier years scaled for the 4-for-1 split before FY2021.
Aligos Therapeutics in its industry: growth against margin (76 companies, SIC 2836)Aligos Therapeutics in its industry: growth against margin (76 companies, SIC 2836)revenue growth, year over year →↑ operating marginmedian +9%median -100%AMGNGILDBIIBMRNANBIXEXELHALOMGTXTECHVIRRGENTARSBCRXALECADMAKRYSIOVATWSTIPSCIMCRVISKVCELADPTNVAXKYMRGLUEIBRXAUTLAGENDNAPLXRXRXFENCCSBRCHRSIVVDCRSPEDITDTILVXRTSTRORGNXCCCCBSEMSCLXACOGTSHASRZNVYGRFDMTLENZXFORELUTFATEOCGNSCTXCRBUCGONDBVTINBXMGXLCTXTCRXDYAIPRMEATRAVitro Biopharma, Inc.HUMARLAYPLURBEAMPROKCRDFAIMVIVSALGS (+282%, -100%)
Biological Products, (No Diagnostic Substances); dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Aligos Therapeutics

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection.

In its own words, from its 8-K, filed Aug 6, 2026.

Aligos Therapeutics against its Biological Products, (No Diagnostic Substances) peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +282% against the peers' median +29%. Operating margin: -773.5% against the peers' median 35.8%.

CompanyQuarterRevenueY/YOp. margin
ALGS Aligos TherapeuticsQ3 2026$2.8M+282%-773.5%
AMGN AmgenQ3 2026$10.4B+8%35.8%
GILD Gilead SciencesQ3 2026$8.3B+7%41.7%
BIIB BiogenQ3 2026$2.8B+11%-0.3%
MRNA ModernaQ3 2026$1.3B+29%9.9%
NBIX Neurocrine BiosciencesQ3 2026$1.1B+41%29.5%
EXEL ExelixisQ3 2026$659M+10%40.8%
HALO Halozyme TherapeuticsQ3 2026$493M+39%59.8%
MGTX MeiraGTx HoldingsQ2 2026$321M87×76.0%

Source: Aligos Therapeutics 10-Q on SEC EDGAR · CIK 1799448 · Biological Products, (No Diagnostic Substances)

Guidance and outlook

Aligos Therapeutics: what its forward-looking statements are about (10-Q filed 2026-11-06)Aligos Therapeutics: what its forward-looking statements are about (10-Q filed 2026-11-06)Costs6Other5Demand2
13 statements; tone +0.54 (−1 all cautious, +1 all confident); 4 hedged.
Aligos Therapeutics: outlook statements against the filing beforeAligos Therapeutics: outlook statements against the filing beforeConfident7

13F: who owns ALGS and who is buying

Largest holders of ALGS (13F)Largest holders of ALGS (13F)Deep Track Capital, LP$2.6MAlyeska Investment Group, L.P.$2.4MSio Capital Management, LLC$1.9MVanguard Group$1.9MMarshall Wace, LLP$1.4MWoodline Partners LP$1.0MVanguard Capital Management LLC$1.0MBaker Bros. Advisors LP$479KHhlr Advisors$440KD. E. Shaw$383K
Funds' net buying of ALGS by quarter (13F)Funds' net buying of ALGS by quarter (13F)$02024-09−$11.2M2024-12$13.8M2025-03−$4.2M2025-06−$562K2025-09$1.4M2025-12−$236K2026-03−$2.8M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ALGS

History

Every quarter: Q3 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare ALGS with

中文版：Aligos Therapeutics（ALGS）财报

Español · Français